Champions Oncology, Inc.: Form 10-Q for the period ended Oct 31, 2025
Filed with the SEC on Dec 15, 2025 and accepted by EDGAR at Dec 15, 2025, 21:59 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-10-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-08-01 to 2025-10-31 | $15.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2025-05-01 to 2025-10-31 | $29.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-08-01 to 2025-10-31 | $7.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-05-01 to 2025-10-31 | $15.3m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2025-08-01 to 2025-10-31 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-05-01 to 2025-10-31 | $4.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-08-01 to 2025-10-31 | $185.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-05-01 to 2025-10-31 | −$342.0k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-08-01 to 2025-10-31 | $18.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2025-05-01 to 2025-10-31 | $33.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-08-01 to 2025-10-31 | $268.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-05-01 to 2025-10-31 | −$169.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-08-01 to 2025-10-31 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-05-01 to 2025-10-31 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-08-01 to 2025-10-31 | $0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-05-01 to 2025-10-31 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-08-01 to 2025-10-31 | 14,457,837 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-05-01 to 2025-10-31 | 13,758,715 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-05-01 to 2025-10-31 | −$1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-05-01 to 2025-10-31 | $288.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-10-31 | $8.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-10-31 | $21.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-10-31 | $30.2m | us-gaap:Assets |
| Current liabilities | At period end2025-10-31 | $22.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-10-31 | $25.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-10-31 | $4.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-25-057082. Last ingested by Listed: Oct 24, 2026, 14:56 ET. Listed shows no prices and gives no investment advice.